Post-Traumatic Stress May Affect Cognition in Breast Cancer Patients

Post-Traumatic Stress May Affect Cognition in Breast Cancer Patients

A new study has found that cognitive decline in breast cancer patients was associated with cancer-related post-traumatic stress, rather than chemotherapy.

Many breast cancer patients report problems of cognitive functioning, and some are considerably burdened by them, according to researchers. These symptoms have mainly been attributed to the neurotoxic effects of chemotherapy, which resulted in the term “chemobrain.”

A longitudinal study in newly diagnosed breast cancer patients from six institutions in Munich, Germany, investigated the role of post-traumatic stress in causing cancer-related cognitive impairment.

In the first year after diagnosis, breast cancer patients — both those treated with and without chemotherapy — showed minimal cognitive dysfunction and decline, which were associated with post-traumatic stress due to having cancer, according to the study’s findings.

“It is well-established that post-traumatic stress — not to be confused with everyday stresses — has disruptive effects on the brain,” said psychologist Dr. Kerstin Hermelink of the Department of Gynecology and Obstetrics at CCC LMU University Hospital of Munich, who led the study.

“For many patients, being diagnosed with breast cancer is a traumatic experience. The hypothesis that cognitive dysfunction in breast cancer patients is caused by post-traumatic stress seemed, therefore, worth pursuing.”

For the study, known as Cognicares (Cognition in Breast Cancer Patients: The Impact of Cancer-Related Stress), researchers recruited 166 newly diagnosed breast cancer patients and 60 women who had undergone routine breast imaging with negative results.

Post-traumatic symptoms in all the women were assessed with a clinical interview, and cognitive function was evaluated with a battery of paper-and-pencil and computer-based neuropsychological tests three times over the course of one year.

In comparison with the control group, the patients showed minimal overall cognitive decline and demonstrated less accuracy on one of several tests of attention before the start of treatment and one year later.

All these deficits were associated with symptoms of post-traumatic stress disorder (PTSD), according to the researchers. They noted that the effect of having breast cancer on attention lost statistical significance if the effect of post-traumatic stress was taken into account.

In contrast, only patients who had received chemotherapy showed longer reaction times than other participants on a test of alertness at one year. The test required pressing a mouse button whenever a cross appeared on a monitor, and the results were unrelated to PTSD symptoms.

“The difference in performance was minimal — 19 milliseconds, on average — and it may at least partly be due to peripheral neuropathy, damage to the nerves of the fingers caused by certain cytostatic agents,” Hermelink said.

The findings of the Cognicares study suggest that psychological factors may contribute more importantly to cancer-related cognitive impairment than neurotoxic effects of treatment, according to the researchers.

“The brain is not a computer that delivers the same level of performance no matter what. Its function and structure are in constant flux, as it reacts and adapts to our experiences and actions,” Hermelink said .

“Indeed, it would be surprising if the psychological consequences and the life disruption brought about by having cancer were not impacting the brain and its functioning.”

While the study focused on the effects of post-traumatic stress, researchers note that other factors, such as insomnia, anxiety and depression — all of which are highly prevalent in breast cancer patients — and lack of cognitive training caused by prolonged sick leave may also affect cognitive function.

“The role of psychological factors, however, has rarely been investigated,” Hermelink said. “In virtually all studies, they were only assessed with self-report screening questionnaires. Given the small effects we are concerned with, these measures are not precise enough.”

The Cognicares study should provide some reassurance for breast cancer patients, according to the researchers.

“Subtle cognitive impairment they may experience does not seem to be an inevitable neurotoxic side-effect of chemotherapy but a consequence of post-traumatic stress and possibly further treatable and modifiable factors,” they conclude.

Source: Ludwig-Maximilians-Universitat Munchen

Read More

Posted by Patricia Adams